3 Stocks With the Most Upside by the End of 2026

The article identifies three stocks with significant upside potential by end of 2026: CRISPR Therapeutics, expected to generate $40M in revenue this year and $160M+ next year as its Casgevy treatment gains traction; Microsoft, trading 40% below analyst price targets as management addresses cloud/AI business challenges; and Recursion Pharmaceuticals, an AI-driven drug discovery platform trading over 100% below analyst consensus with multiple developmental milestones approaching.

07/30/2026, 4:30 PM • The Motley Fool

Cathie Wood's Ark Bought $21.3 Million of SpaceX Stock as Shares Fell 45% From Their Record High. Wall Street's Median Price Target Is $243.81, 111.5% Above the Current Close.

Cathie Wood's Ark Investment Management purchased $21.3 million in SpaceX stock as shares fell 45% from their record high and now trade below the IPO price of $135. Wall Street analysts have a median 12-month price target of $243.81, representing 111% upside, though opinions vary widely. SpaceX's massive $28.5 trillion total addressable market opportunity, particularly in AI, drives bullish sentiment, though the company remains unprofitable and faces significant uncertainty.

07/27/2026, 5:25 AM • The Motley Fool

Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating

Cathie Wood's Ark Investment Management holds $362 million in CRISPR Therapeutics across two ETFs. While known for gene-editing work like the FDA-approved Casgevy, the company is quietly developing CAR T-cell therapies that could address a market projected to exceed $60 billion annually by 2034. CRISPR's off-the-shelf CAR T approach using donor cells could reduce costs compared to patient-specific treatments, positioning it competitively despite being in early trial stages.

07/22/2026, 5:30 AM • The Motley Fool

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?

Cathie Wood's Ark Invest has significantly increased its position in Beam Therapeutics, a biotech company using base editing technology for genetic treatments. With multiple clinical programs advancing toward FDA approval and sufficient cash runway through mid-2029, Beam could transform into a commercial biotech company. However, the investment remains speculative and dependent on successful clinical trials and regulatory approvals.

07/20/2026, 1:30 PM • The Motley Fool

Vertex’s Crinetics Deal Balances Growth with Integration Risk

Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals at $85 per share, representing a 102% premium to the pre-announcement price. The deal aims to expand Vertex beyond its core cystic fibrosis business into rare disease therapeutics, with immediate revenue from FDA-approved PALSONIFY for acromegaly and Phase 3 candidate Atumelant for congenital adrenal hyperplasia. While analysts view the strategic fit positively, the deal presents integration risks and questions about pipeline depth.

07/08/2026, 10:22 AM • Investing

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article compares two biotech companies: CRISPR Therapeutics, which has achieved its first gene-editing product approval for sickle cell disease but faces significant losses and customer concentration risks, versus Viking Therapeutics, a clinical-stage company targeting the obesity and metabolic disorder markets with no approved products yet. While both are highly speculative, the author favors CRISPR due to its existing revenue and approved treatment, despite Viking's potentially larger market opportunity.

07/06/2026, 7:35 AM • The Motley Fool

Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth Forecast

The global gene editing therapeutics market is projected to grow from USD 0.36 billion in 2026 to USD 0.65 billion by 2031, driven by CRISPR advancements, precision medicine adoption, and increased pharma investments. Key applications include oncology and rare genetic disorders, though high development costs, regulatory complexity, and safety concerns remain significant challenges.

07/03/2026, 4:44 AM • GlobeNewswire

Global CRISPR-Based Drug Development Platforms Market to Reach USD 0.79 Billion by 2031: Precision Medicine and Gene Therapy Drive Growth

The CRISPR-based drug development platforms market is projected to grow at a CAGR of 11.4%, reaching USD 0.79 billion by 2031 from USD 0.46 billion in 2026. Growth is driven by advancements in precision medicine, gene therapy expansion, and increased biotech investments, though regulatory challenges and high development costs remain constraints.

07/03/2026, 4:41 AM • GlobeNewswire

Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?

The article compares two biotech companies with different risk profiles: Ocular Therapeutix, which has commercial revenue from its Dextenza product and is preparing an FDA application for Axpaxli, versus Prime Medicine, which is developing early-stage Prime Editing gene therapy technology. Despite Prime Medicine's moonshot potential, Ocular Therapeutix is recommended as the better choice for average investors in 2026 due to its more advanced development stage and clearer investment thesis, though both remain high-risk biotech plays.

06/15/2026, 4:10 PM • The Motley Fool

CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential

CRISPR Therapeutics trades at a significant discount despite Wall Street analysts rating 58% as buy with 437% upside potential. The company's first commercialized product, Casgevy, treats sickle cell disease and beta thalassemia. With only 64 patients treated in 2025 and $4.1M in sales, analysts project revenue growth to $43.9M in 2026 and $151.6M in 2027. A strong pipeline of five additional therapies in clinical trials and a large addressable market of 60,000 eligible patients position CRISPR as a potential long-term growth opportunity, though highly speculative.

06/03/2026, 12:30 PM • The Motley Fool

CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking

CRISPR Therapeutics acquired CTX611, a clinical-stage siRNA therapy targeting Factor XI for blood clot prevention, for $95 million upfront. The program could significantly impact the company's revenue despite being a follower in a competitive anticoagulant market dominated by Eliquis and other therapies. With only $1.4 million in Q1 2026 revenue, success with CTX611 could be transformative for the stock.

06/01/2026, 12:30 PM • The Motley Fool

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?

The article compares two gene-editing biotech companies: CRISPR Therapeutics, which has FDA-approved CASGEVY therapy and stronger financials, versus Editas Medicine, which focuses on in vivo gene editing but lacks FDA approval and has a weaker balance sheet. CRISPR Therapeutics is recommended as the better 2026 investment due to its commercial-stage advantage, stronger cash position, and lower financial risk, despite Editas offering potentially greater upside if successful.

05/31/2026, 12:11 PM • The Motley Fool

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?

The article compares two gene-editing biotech companies: CRISPR Therapeutics, which has an approved product (Casgevy) and a deeper pipeline, versus Beam Therapeutics, a clinical-stage company with a potentially safer base-editing platform. CRISPR Therapeutics is recommended as the better investment due to its approved product, stronger cash position ($2.4B vs $1.2B), and deeper pipeline, making it less risky despite both stocks carrying clinical trial risks.

05/25/2026, 8:35 PM • The Motley Fool

1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?

CRISPR Therapeutics has bullish analyst sentiment with Piper Sandler's Edward Tenthoff setting a $110 price target, implying over 100% upside. The biotech's prospects are supported by upcoming clinical trial data for CTX611 (an anticoagulant targeting a $20B market), expansion of its approved Casgevy gene therapy to children, and a deep pipeline. However, the stock remains risky due to dependence on positive clinical results and execution.

05/11/2026, 4:15 PM • The Motley Fool

Is This Millionaire-Maker Biotech Stock a Buy Right Now?

Vertex Pharmaceuticals has been a strong long-term performer but faces challenges with slowing growth in its core cystic fibrosis business and struggles diversifying into new markets. However, the company shows promise with upcoming approvals for gene-editing therapy Casgevy and kidney disease treatment povetacicept, which could drive future growth and make it attractive at current levels.

05/06/2026, 3:30 AM • The Motley Fool